Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BioLineRx Ltd. (NASDAQ: BLRX).

Full DD Report for BLRX

You must become a subscriber to view this report.


Recent News from (NASDAQ: BLRX)

BioLineRx to Present at 20th Annual Rodman & Renshaw Global Investment Conference in New York
TEL AVIV, Israel , August 30, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that its Chief Executive Officer, Philip Serlin , will present a company update at the 20th...
Source: PR Newswire
Date: August, 30 2018 07:00
BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q2 2018 Results - Earnings Call Transcript
BioLineRx Ltd. (BLRX) Q2 2018 Results Earnings Conference Call August 13, 2018 10:00 AM ET Executives Vivian Cervantes - PCG Advisory Phil Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Abi Vainstein - Vice President, Clinical and Medical Affairs Analy...
Source: SeekingAlpha
Date: August, 13 2018 14:34
Biolinerx reports Q2 results
Biolinerx ( BLRX ) Q2 results : Revenues: $0; R&D Expense: $4.5M (+9.8%); SG&A: $0.4M (+33.3%); Net Loss: ($4.8M) (+2.0%); Loss Per Share: ($0.05) (unch); CF Flow Ops: ($13M) (-62.5%). More news on: BioLineRx Ltd., Healthcare stocks news, Earnings news and commentary, , Read m...
Source: SeekingAlpha
Date: August, 13 2018 07:30
BioLineRx Reports Second Quarter 2018 Financial Results
TEL AVIV, Israel , Aug. 13, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the second quarter ended June 30, 2018 . Highlights and achievements d...
Source: PR Newswire
Date: August, 13 2018 07:00
3 Things In Biotech, August 8: Spark's Downtrodden, Array's Broken Through
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Array gets deeper in colorectal cancer Company : Array BioPharma (ARRY) Therapy : B...
Source: SeekingAlpha
Date: August, 08 2018 08:00
BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
TEL AVIV, Israel , August 7, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today positive results from the lead-in period of the GENESIS trial, a double-blind, placebo-controlled ...
Source: PR Newswire
Date: August, 07 2018 07:00
BioLineRx to Report Second Quarter 2018 Results on August 13, 2018
TEL AVIV, Israel , Aug. 6, 2018 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today it will release its unaudited financial results for the quarter ended June 30, 2018 on M...
Source: PR Newswire
Date: August, 06 2018 06:36
Your Daily Pharma Scoop: Theravance Positive, Denali Encouraging, Redhill Clarifies Data
Stocks in News: TBPH, DNLI Theravance's TD-9855 shows positive effect in low blood pressure disorder study Theravance Biopharma ( TBPH ) reported positive data of a four-week data from a Phase 2 clinical trial of TD-9855. The candidate is an once-daily norepinephrine and serotonin reup...
Source: SeekingAlpha
Date: August, 03 2018 00:56
BioLineRx launches Phase 1/2a study of AGI-134 in solid tumors
BioLineRx (NASDAQ: BLRX ) initiates an open-label Phase 1/2a clinical trial evaluating AGI-134, as monotherapy and in combination with an immune checkpoint inhibitor, in patients with unresectable solid tumors. More news on: BioLineRx Ltd., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 01 2018 09:28
BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
TEL AVIV , Israel , August 1, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has initiated a Phase 1/2a clinical study for AGI-134, a novel compound that evokes a d...
Source: PR Newswire
Date: August, 01 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-110.6850.6510.690.631442,241
2018-12-100.65560.66250.6720.6373401,421
2018-12-070.66010.65140.680.645171,003
2018-12-060.660.65840.67010.6451,473,156
2018-12-050.680.6610.680.66228,203

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-11119,779229,56552.1765Short
2018-12-1075,671128,67958.8060Short
2018-12-0745,15262,64372.0783Short
2018-12-06430,304720,88959.6907Short
2018-12-0460,030141,57142.4028Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BLRX.


About BioLineRx Ltd. (NASDAQ: BLRX)

Logo for BioLineRx Ltd. (NASDAQ: BLRX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: BLRX)

      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 17 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 17 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: May, 16 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 24 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 24 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 16 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: April, 16 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 02 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 02 2018
      Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
      Filing Type: 6-KFiling Source: edgar
      Filing Date: March, 26 2018

       

       


      Daily Technical Chart for (NASDAQ: BLRX)

      Daily Technical Chart for (NASDAQ: BLRX)


      Stay tuned for daily updates and more on (NASDAQ: BLRX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: BLRX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BLRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BLRX and does not buy, sell, or trade any shares of BLRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/